| Israël | Turquie | Espagne | |
| Tests de mutation KRAS, NRAS, BRAF | de $750 | de $150 | de $550 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Tests de mutation KRAS, NRAS, BRAF. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Tests de mutation KRAS, NRAS, BRAF.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Tests de mutation KRAS, NRAS, BRAF et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Tests de mutation KRAS, NRAS, BRAF.
Dr. Auala Hubert is a board-certified medical oncologist and radiotherapist with 33 years of clinical experience. She works at Hadassah Medical Center and speaks both English and Hebrew. Dr. Hubert leads the Gastrointestinal Cancer Center. She is also a senior physician in the Oncology Department.
She earned her M.D. from Hadassah University Hospital. She holds board certifications in oncology and radiotherapy. Dr. Hubert has passed USMLE Parts I and II. She is a member of the Israel Society of Clinical Oncology, Israel Medical Society, and Israel Cancer Association. Dr. Hubert also serves on several medical and social service committees, where she helps advance cancer care.
Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.
He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.
He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.